首页> 美国卫生研究院文献>other >Phase 1/1b dose escalation and expansion study of BEZ235 a dual PI3K/mTOR inhibitor in patients with advanced solid tumors including patients with advanced breast cancer

【2h】

Phase 1/1b dose escalation and expansion study of BEZ235 a dual PI3K/mTOR inhibitor in patients with advanced solid tumors including patients with advanced breast cancer

机译：BEZ235（PI3K / mTOR双重抑制剂）在晚期实体瘤患者（包括晚期乳腺癌）中的1 / 1b剂量递增和扩展研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeTo determine the maximum tolerated dose (MTD) of BEZ235, an oral inhibitor of class I PI3K and mTOR complexes 1 and 2.

机译：目的确定BEZ235（I类PI3K和mTOR复合物1和2的口服抑制剂）的最大耐受剂量（MTD）。

著录项

期刊名称 other
作者
Jordi Rodon; Alejandro PérezFidalgo; Ian E. Krop; Howard Burris; Angel Guerrero-Zotano; Carolyn D. Britten; Carlos Becerra; Jan Schellens; Donald A. Richards; Martin Schuler; Maysa Abu-Khalaf; Faye M. Johnson; Malcolm Ranson; Jeff Edenfield; Antonio P. Silva; Wolfgang Hackl; Cornelia Quadt; David Demanse; Vincent Duval; Jose Baselga;
展开▼
作者单位

展开▼
年(卷),期 -1(82),2
年度 -1
页码 285–298
总页数 22
原文格式 PDF
正文语种
中图分类
关键词
PI3K mTORC1/2 Breast cancer BEZ235 Inhibitor;

机译：PI3K;mTORC1 / 2;乳腺癌;BEZ235;抑制剂;

相似文献

外文文献
中文文献
专利

1. Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer [J] . Rodon Jordi, Perez-Fidalgo Alejandro, Krop Ian E., Cancer chemotherapy and pharmacology. . 2018,第2期

机译：在患有先进乳腺癌的患者的患者中，BEZ235，双PI3K / MTOR抑制剂的BEZ235，双PI3K / MTOR抑制剂的升级和膨胀研究
2. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13) [J] . Wicki Andreas, Brown Nicholas, Xyrafas Alexandros, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：先进实体肿瘤患者口服双PI3K和MTORC1 / 2抑制剂PQR309的首先人，第1期，剂量 - 升级药代动力学和药效学研究（SAKK 67/13）
3. A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors [J] . Johanna C. Bendell, Carla Kurkjian, Jeffrey R. Infante, Investigational New Drugs . 2015,第2期

机译：晚期实体瘤患者每日两次（BID）口服PI3K / mTOR双重抑制剂BEZ235香囊制剂的1期研究
4. Characterizing tumor changes during neoadjuvant treatment of locally advanced breast cancer patients (LABC) using dynamicenhanced magnetic resonance imaging (DE-MRI) [C] . Oana I. Craciunescu, Ellen L. Jones, Kimberly L. Blackwell, Society of Photo-Optical Instrumentation Engineers (SPIE);SPIE Proceedings . 2005

机译：使用动态增强磁共振成像（DE-MRI）表征局部晚期乳腺癌患者（LABC）新辅助治疗期间的肿瘤变化
5. Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-Clinical Mechanistic Assessment [D] . Moorthy, Ganesh P. 2015

机译：BEZ235，PI3K / mTOR抑制剂和依维莫司，mTOR抑制剂的新型组合的临床药代动力学：I期临床研究和非临床机制评估
6. A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours [O] . Alison M. Schram, Leena Gandhi, Monica M. Mita, 2018

机译：晚期实体瘤患者口服MEK抑制剂pimasertib和PI3K / MTOR抑制剂voxtalisib的Ib期剂量递增和扩展研究
7. A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours [O] . Alison M. Schram, Leena Gandhi, Monica M. Mita, 2018

机译：患有先进实体肿瘤的患者口服梅克抑制剂Pimasertib和PI3K / MTOR抑制剂Voxtalisib的IB剂量 - 升级和扩展研究

Phase 1/1b dose escalation and expansion study of BEZ235 a dual PI3K/mTOR inhibitor in patients with advanced solid tumors including patients with advanced breast cancer

摘要

著录项

相似文献

相关主题

期刊订阅